BioNTech, Pfizer Receive EMA Recommendation for COVID-19 Vaccine Approval
ByAinvest
Friday, Jul 25, 2025 11:39 am ET1min read
BNTX--
The LP.8.1-adapted vaccine has shown improved immune responses against currently dominant and emerging SARS-CoV-2 lineages compared to the 2024-2025 vaccine formulations [2]. This adaptation aims to maintain the effectiveness of the vaccines as the virus continues to evolve.
The CHMP's recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the LP.8.1-adapted vaccine to ensure supply readiness ahead of the upcoming fall and winter season [3].
The COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech's proprietary mRNA technology and have demonstrated a favorable safety and efficacy profile supported by extensive real-world evidence, clinical, non-clinical, pharmacovigilance, and manufacturing data [3].
References:
[1] https://www.rttnews.com/3557477/pfizer-biontech-receive-positive-chmp-opinion-for-lp-8-1-adapted-covid-19-vaccine.aspx
[2] https://seekingalpha.com/news/4472112-pfizer-biontech-win-eu-backing-new-covid-shot
[3] https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-receive-positive-chmp-opinion-lp81-adapted-0?mobile=1
MRNA--
PFE--
BioNTech SE and Pfizer Inc. announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for their LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY LP.8.1) for individuals 6 months of age and older. The vaccine is designed to prevent COVID-19 caused by SARS-CoV-2. The companies are developing a COVID-19 vaccine, the BNT162b2 mRNA vaccine program, and the Pfizer-BioNTech COVID-19 Vaccine, also known as COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2).
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Pfizer Inc. (PFE) and BioNTech SE (BNTX)'s LP.8.1-adapted monovalent COVID-19 vaccine, COMIRNATY LP.8.1, for individuals aged 6 months and older [1]. The recommendation is based on the EMA's Emergency Task Force (ETF) recommendation to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season.The LP.8.1-adapted vaccine has shown improved immune responses against currently dominant and emerging SARS-CoV-2 lineages compared to the 2024-2025 vaccine formulations [2]. This adaptation aims to maintain the effectiveness of the vaccines as the virus continues to evolve.
The CHMP's recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the LP.8.1-adapted vaccine to ensure supply readiness ahead of the upcoming fall and winter season [3].
The COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech's proprietary mRNA technology and have demonstrated a favorable safety and efficacy profile supported by extensive real-world evidence, clinical, non-clinical, pharmacovigilance, and manufacturing data [3].
References:
[1] https://www.rttnews.com/3557477/pfizer-biontech-receive-positive-chmp-opinion-for-lp-8-1-adapted-covid-19-vaccine.aspx
[2] https://seekingalpha.com/news/4472112-pfizer-biontech-win-eu-backing-new-covid-shot
[3] https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-receive-positive-chmp-opinion-lp81-adapted-0?mobile=1
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet